{"filings":[{"id":2105996,"accession_number":"0001846253-26-000044","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-08-06T20:11:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q2 revenue surges to $13.4M; raises full-year 2026 revenue and cash outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 revenue $13.4M vs $3.9M YoY, driven by milestone revenue and new ion channel programs.","R&D expense $9.6M vs $10.9M YoY; G&A $6.7M vs $7.7M; total costs flat at $20.1M.","Raises full-year 2026 revenue and cash outlook citing continued business momentum.","Appointed Amechi Nwachuku as COO to drive xPloration platform growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1592316,"accession_number":"0001846253-26-000042","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-07-13T12:06:34+00:00","items":["5.02"],"status":"ready","headline":"OmniAb appoints Amechi Nwachuku as COO effective July 13, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amechi Nwachuku appointed COO, effective July 13, 2026; most recently VP at Thermo Fisher Scientific.","Initial annual base salary of $445,000; eligible for annual target bonus of 45% of base salary.","Received $20,000 signing bonus; granted stock options to purchase 800,000 shares vesting over 4 years.","Options vest 12.5% at six-month anniversary, then monthly; exercise price equals closing price on grant date.","Eligible for severance under OmniAb Severance Plan and change-in-control agreement with enhanced benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1139236,"accession_number":"0001846253-26-000039","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-06-18T20:29:10+00:00","items":["5.07"],"status":"ready","headline":"OmniAb shareholders elect directors Cochran and Foehr, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jennifer Cochran, Ph.D. elected with 57,948,696 votes for, 25,997,984 withheld, 18,464,904 broker non-votes.","Matthew W. Foehr elected with 82,231,849 votes for, 1,714,831 withheld, 18,464,904 broker non-votes.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 102,163,551 for, 112,653 against, 135,380 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96170,"accession_number":"0001846253-26-000035","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 revenue $14.4M vs $4.2M YoY; raises 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue Q1 2026 $14.4M (up 243% YoY) driven by milestone revenue.","R&D expense $9.6M (down 24% YoY); G&A expense $6.6M (down 16% YoY).","Amortization included $2.9M non-cash impairment from discontinued small-molecule programs.","Cash operating expenses (non-GAAP) $12.3M, down from $14.7M YoY.","2026 revenue guidance raised; management highlights OmniUltra launch and partner progress."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":14427000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109845,"accession_number":"0001846253-26-000006","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 net loss $14.2M; FY 2025 revenue down 29% YoY; guides 2026 rev $25-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $8.4M (down 22% YoY from $10.8M); net loss $14.2M ($0.11/share).","Full year 2025 revenue $18.7M (down 29% from $26.4M); net loss $64.8M ($0.57/share vs $0.61).","Ended 2025 with 107 active partners and 407 active programs; cash $54.0M.","2026 guidance: revenue $25-30M, costs/opex $80-85M, cash costs $50-55M.","Recorded $3.9M impairment charge and $3.0M gain from sale of Kv7.2 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109844,"accession_number":"0001846253-26-000002","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"OmniAb amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws effective January 30, 2026, adding universal proxy rule compliance language.","Stockholder nominations must comply with Rule 14a-19 and include expanded background and ownership disclosures.","Enhanced procedural requirements for stockholder proposals, including details on proxy solicitation.","Amendments also include technical, modernizing, and clarifying changes to the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126382,"accession_number":"0001628280-25-048850","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 revenue falls 48% to $2.2M; net loss $0.14; raises FY revenue guidance to $18-22M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M vs $4.2M in Q3 2024, driven by lower milestones and service revenue from discontinued ion channel programs.","Net loss $16.5M ($0.14/share), nearly flat vs $16.4M loss in prior year; nine-month loss $50.6M.","Raised $30M via private placement in August; cash & equivalents $59.5M as of Sep 30.","FY 2025 guidance: revenue $18-22M, operating expense $82-86M, year-end cash $52-56M; 0% tax rate.","New partners A*Star, University of Leeds, Dana-Farber; OmniUltra platform launch expected Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":10290000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143145,"accession_number":"0001193125-25-186981","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"OmniAb raises $30M via private placement of 21.3M shares at $1.40/$1.85 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 21,254,106 common shares at $1.40 (or $1.85 for insiders) for gross proceeds of ~$30M.","Net proceeds to be used for working capital and general corporate purposes.","Expected to close on Aug 26, 2025; Leerink Partners acting as sole placement agent.","Company to file resale registration statement with SEC within 45 days after close; 60-day lock-up for insiders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143144,"accession_number":"0001846253-25-000064","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb reports Q2 2025 revenue $3.9M, net loss $15.9M; affirms $20-25M FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $3.9M (down 49% YoY) on lower milestone and service revenue; net loss $15.9M ($0.15/sh) vs $13.6M ($0.13) in Q2 2024.","2025 guidance: revenue $20M-$25M, operating costs $85M-$90M, cash use expected below 2024's $38.9M (ex-ATM).","100 active partners and 381 active programs as of June 30, 2025, including 32 OmniAb-derived programs in clinical development.","Sold small-molecule Kv7.2 program to Angelini Pharma for $3M upfront; eligible for >$170M milestones plus royalties.","Launched xPloration Partner Access Program for high-throughput B-cell screening; xPloration won 2025 Best of Show at PEGS Boston."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":8051000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161259,"accession_number":"0001846253-25-000059","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OmniAb shareholders elect two Class III directors and ratify EY auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Carolyn R. Bertozzi, Ph.D. elected with 36,153,128 votes for, 31,275,065 withheld, 16,933,628 broker non-votes.","John Higgins elected with 53,835,964 votes for, 13,592,229 withheld, 16,933,628 broker non-votes.","Ratification of Ernst & Young as auditor for 2025 approved: 84,233,643 for, 110,544 against, 17,634 abstain.","No other matters were submitted to a vote; meeting held on June 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161258,"accession_number":"0001846253-25-000053","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 2025 revenue $4.2M (+10% YoY), net loss $18.2M; lowers opex guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $4.2M (vs $3.8M in Q1 2024); net loss $18.2M ($0.17/share) vs $19.0M ($0.19/share) prior year.","Cash $43.6M at March 31, 2025; FY2025 revenue guidance reaffirmed $20-25M; opex guidance lowered to $85-90M from $90-95M.","Entered three new platform license agreements (Wyss, Takis, Orion); Orion deal includes $250K upfront and >$55M milestones.","Post-quarter asset sale to Angelini Pharma for Kv7.2 program: $3M upfront, >$170M milestones plus royalties.","Partner updates: Immunovant batoclimab positive MG/CIDP results; Teva Phase 2 celiac trial; Sugemalimab EMA submission."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":4154000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161257,"accession_number":"0001846253-25-000034","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OmniAb appoints two new independent directors; Sarah Boyce resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sarah Boyce resigned from Board and all committees effective April 18; no disagreement with company.","Steven C. Crouse and Philip J. Gotwals appointed as Class II directors, terms expiring at 2027 annual meeting.","Crouse (Bio-Techne SVP) and Gotwals (former Novartis BD head) bring life sciences and biopharma expertise.","Each received initial equity grants: RSUs for 40,000 shares and options for 80,000 shares.","Board size increased from six to seven; new directors deemed independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179410,"accession_number":"0001846253-25-000022","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 rev $10.8M, net loss $13.1M; guides FY25 rev $20-25M, opex $90-95M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $10.8M (up from $4.8M YoY); net loss $13.1M ($0.12/shr) vs $14.1M loss prior year.","FY2024 revenue $26.4M (down from $34.2M); net loss $62.0M ($0.61/shr) vs $50.6M loss in 2023.","Cash and investments $59.4M at Dec 31, 2024; expects 2025 cash use below 2024's $38.9M.","2025 guidance: revenue $20-25M, operating expense $90-95M, effective tax rate ~0%.","91 active partners, 363 active programs; 10 new license agreements in 2024 (incl. Incyte, Photinia)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196115,"accession_number":"0001846253-24-000086","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.","Cash $59.4M at Sept 30; sold 2.0M shares via ATM for $8.5M in Q3, plus $2.9M post-quarter.","FY 2024 total opex expected slightly below 2023; FY 2024 cash balance guided at $50-60M.","Entered three new platform licenses in Q3 (92Bio, MSKCC, Queen Mary London) plus Incyte after quarter.","Partner events: Immunovant IMVT-1402 IND cleared in RA; Genmab to start Ph3 for acasunlimab; CStone sugemalimab UK approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":15587000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212388,"accession_number":"0001846253-24-000071","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q2 revenue $7.6M, net loss $0.13/sh; guides 2024 opex slightly below 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.6M (+10% YoY), net loss $13.6M ($0.13/sh) vs $14.7M loss in Q2 2023.","H1 2024 revenue $11.4M vs $23.9M (prior year included $10M TECVAYLI milestone); net loss $32.6M ($0.32/sh).","Cash $57.2M at June 30; expects 2024 opex slightly below 2023, cash use similar to 2023 ex-$35M milestone.","New platform licenses with DAAN Bio, Topaz Therapeutics, HanAll Biopharma; post-Q2 deals with 92Bio and Memorial Sloan Kettering.","GSK discontinued Nav1.1 program (OmniAb retains co-ownership); Roche returning Kv7.2 rights (not due to scientific reasons)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":11415000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212387,"accession_number":"0001846253-24-000063","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Joshua Tamaroff resigns from OmniAb Board; Audit Committee vacancy filled","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joshua Tamaroff resigned from Board and Audit Committee effective June 28, 2024, due to pending departure from Avista Capital Partners.","No disagreement with Company or management cited.","Avista does not intend to designate a successor director.","Board reduced from seven to six members; Sarah Boyce appointed to Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231322,"accession_number":"0001846253-24-000045","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OmniAb shareholders elect Boyce and Love as Class II directors; ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders elected Sarah Boyce and Steve Love as Class II directors for three-year terms expiring 2027.","Boyce received 61,512,919 votes for and 19,906,776 withheld; Love received 80,325,457 for and 1,094,238 withheld.","Broker non-votes on director election totaled 14,109,982.","Ratification of Ernst & Young as independent auditor for FY 2024 passed with 93,272,240 votes for, 2,195,483 against, and 61,954 abstain.","No broker non-votes on auditor ratification proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231321,"accession_number":"0001846253-24-000032","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 2024 revenue drops to $3.8M; net loss widens to $19.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M vs $16.9M YoY; net loss $19.0M ($0.19/share) vs $6.1M ($0.06/share) loss.","Cash and short-term investments $69.0M; expects 2024 cash use similar to 2023 excluding $35M milestone.","Signed three new license agreements; 80 active partners, 327 active programs, 31 in clinic.","Pipeline: batoclimab MG Phase 3 topline H2 2024; IMVT-1402 plans 4-5 registrational programs.","Guidance: 2024 operating expense flat vs 2023; cash use substantially lower in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":3801000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249748,"accession_number":"0001628280-24-012222","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 revenue $4.8M, net loss $14.1M; 77 partners, 32 programs in clinic; guides 2024 op ex flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $4.8M vs $35.3M in Q4 2022, primarily due to $25M milestone in prior year.","Full-year 2023 net loss $50.6M ($0.51/share) vs net loss $22.3M ($0.26) in 2022.","Operating cash flow $2.3M; cash and investments $87.0M at Dec 31, 2023.","2024 operating expense expected flat vs 2023; cash use expected to decline substantially in 2025.","10 new licenses signed in 2023, 6 new antibodies entered clinic; launched OmniDeep and Omni dAb platforms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267193,"accession_number":"0001846253-23-000117","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 revenue falls 20% to $5.5M; net loss widens to $15.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 revenue $5.5M (down 20% YoY); net loss $15.7M ($0.16/share) vs $12.6M loss in Q3 2022.","Active partner programs 314, up from 291 at year-start; added Novartis, GigaMune, Polaris as new partners.","Cash & short-term investments $96.6M at Sep 30; expects year-end cash slightly below year-end 2022.","Nine-month revenue $29.3M (up 24% YoY) from milestone payments; net loss $36.6M ($0.37/share).","Appointed Steve Love to Board (Audit Chair) and Yasmina Abdiche as VP of Exploratory Research."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":29342000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267192,"accession_number":"0001846253-23-000102","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"OmniAb appoints Steven Love to Board of Directors, effective Nov 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Love appointed to Board; will serve as Chair of Audit Committee and member of Compensation Committee.","Love is CFO of Heap Inc., a SaaS analytics company; previously CFO at multiple tech firms.","Granted RSUs for 40,000 shares and options for 80,000 shares, vesting over three years.","Cash compensation per director policy; determined independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284475,"accession_number":"0001846253-23-000093","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.","H1 revenue $23.9M (vs $16.8M) driven by $10M milestone from TECVAYLI first commercial sale in EU.","Added 4 new partners: Merck, Neurocrine, Stanford, Seattle Children's; total active programs 305.","Batoclimab BLA accepted in China for gMG; IMVT-1402 Phase 1 initiated; GSK milestone $2.0M earned.","Cash and equivalents $103.1M; expects year-end cash slightly higher than 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":23865000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304160,"accession_number":"0001846253-23-000082","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"OmniAb stockholders elect two Class I directors and ratify auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Matthew W. Foehr and Jennifer Cochran, Ph.D. elected as Class I directors for three-year terms expiring 2026.","Foehr received 73,222,386 votes for; Cochran received 69,340,824 votes for.","Ratification of Ernst & Young LLP as independent auditor for fiscal 2023 passed with 87,761,330 votes for.","Broker non-votes: 13,703,592 for director elections; none for auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304159,"accession_number":"0001846253-23-000064","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q1 2023 revenue $16.9M, net loss $6.1M; 301 active partner programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $16.9M, up from $9.6M YoY, driven by $10.0M milestone from TECVAYLI EU commercial sale.","Net loss $6.1M ($0.06/share) vs $6.3M ($0.08/share) YoY; cash & investments $113.6M.","301 active programs, 27 in clinical/commercial; new license with Neurocrine Biosciences post-quarter.","Introduced OmniDeep in silico platform; Seagen's SGN-BB228 entered Phase 1 for melanoma.","Immunovant expects Phase 2 Graves' disease results H2 2023; CStone sBLA for sugemalimab in ESCC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":16919000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323832,"accession_number":"0001846253-23-000033","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OmniAb amends auditor consent to fix typographical error in report date","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Corrected date of Ernst & Young auditor's report in Exhibit 23.2 to 10-K for year ended Dec 31, 2022.","No changes to financial statements or other disclosures; purely administrative correction.","Amendment filed on March 31, 2023, one day after original 10-K filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323831,"accession_number":"0001846253-23-000024","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q4 revenue $35.3M, net income $6.8M; record 13 new partnerships in 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $35.3M (up from $15.3M YoY) driven by $25M TECVAYLI milestone; net income $6.8M vs loss of $3.1M.","Full year 2022 revenue $59.1M (up from $34.7M); net loss $22.3M ($0.26/share) vs $27.0M loss in 2021.","Cash and short-term investments $88.3M at Dec 31, 2022; received additional $35M in Jan 2023 from Janssen.","Signed 13 new licenses in 2022; 26 OmniAb-derived programs in clinic/commercial; 291 total programs.","Expects $10M milestone from TECVAYLI EU approval in 2023; 2023 year-end cash slightly higher than 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323830,"accession_number":"0001193125-23-004752","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"OmniAb reports preliminary year-end cash of ~$88M; attending J.P. Morgan conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2022: approximately $88M.","Estimate is subject to completion of financial closing procedures and audit, may change materially.","Company representatives attending J.P. Morgan Healthcare Conference starting Jan 9, 2023.","Updated corporate presentation posted on OmniAb's website; no further 8-K updates planned for future changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341818,"accession_number":"0001193125-22-288305","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OmniAb expects $25M milestone payment from Janssen after first US commercial sale of TECVAYLI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Janssen notified OmniAb that first US commercial sale of TECVAYLI (teclistamab) occurred, triggering $25M milestone.","OmniAb expects to receive the $25M payment and recognize $25M milestone revenue in Q4 2022.","Milestone arises from licensing agreement between OmniAb and an affiliate of Janssen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341817,"accession_number":"0001193125-22-285236","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OmniAb Q3 2022 revenue $6.9M, net loss $12.6M; completed spin-off from Ligand","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $6.9M in Q3 2022 vs $6.3M in Q3 2021; net loss $12.6M vs $7.9M.","Completed tax-free spin-off from Ligand and merger with Avista on Nov 1, 2022; net cash ~$96M.","68 active partners; 25 OmniAb-derived programs in clinic/commercial; 282 partner programs.","Janssen received FDA and EU approval for TECVAYLI; OmniAb eligible for up to $35M in milestones.","New platform deals with Dianthus, Hillstream, NGM Bio, TriPhase, Talem, and a stealth biotech."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":23732000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341815,"accession_number":"0001193125-22-284536","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K/A","filed_at":"2022-11-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"OmniAb reports $23.7M revenue, $29.2M net loss for nine months ended Sep 30, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue for nine months ended Sep 30, 2022 was $23.7M, up 22% from $19.5M in 2021.","Net loss widened to $29.2M from $24.0M a year earlier, driven by higher R&D and G&A expenses.","Post-closing of business combination, New OmniAb had approximately $95.8M in net cash.","Company expects to continue incurring losses as it invests in platform and public company costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341816,"accession_number":"0001193125-22-279194","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["1.01","2.01","5.06","3.02","3.03","5.03","5.01","5.02","9.01"],"status":"ready","headline":"OmniAb completes business combination with Avista Public Acquisition Corp. II, begins trading on Nasdaq","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed on Nov 1, 2022; APAC domesticated as OmniAb, Inc. (DE) and merged with Legacy OmniAb.","Redemption of 21.7M APAC shares at ~$10.32/share consumed $224M from trust; remaining ~$13.3M transferred to OmniAb.","Sponsor purchased 10.2M shares and 3.1M warrants for $101.7M via Forward Purchase and Redemption Backstop.","Legacy OmniAb shareholders received 82.6M OmniAb shares + 15M earnout shares; earnout vests at $12.50 and $15.00 VWAP.","OmniAb common stock (OABI) and warrants (OABIW) started trading on Nasdaq on Nov 2, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341814,"accession_number":"0001193125-22-279213","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K/A","filed_at":"2022-11-07T23:59:59+00:00","items":["4.01","5.03","5.05","8.01","9.01"],"status":"ready","headline":"OmniAb files 8-K/A: Auditor changed to EY, pro forma shows $390.6M assets, 114.8M shares outstanding after SPAC close","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Marcum as auditor, engaged EY as new independent registered public accounting firm effective Nov 1, 2022.","Pro forma shows 114.8M shares outstanding; Legacy OmniAb stockholders hold 85%, Sponsor 13.9%, public 1.1%.","APAC public shareholders redeemed 21.7M shares for ~$224M ($10.32/share), leaving only 1.3M public shares.","Adopted new certificate of incorporation, bylaws, and code of business conduct and ethics.","OmniAb became successor issuer; OABI and OABIW now registered under Section 12(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341813,"accession_number":"0001104659-22-110957","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Avista Public Acquisition Corp. II shareholders approve OmniAb business combination; ~97% of public shares redeemed","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All proposals approved at Oct 24 meeting including business combination, domestication, governance, director elections.","21.7M Class A shares redeemed at ~$10.32/share ($224M total), leaving limited trust cash; Sponsor backstops redemptions.","Sponsor to receive ~8.7M shares & ~1.4M warrants for $86.7M backstop, plus $15M private placement for 1.5M shares & 1.67M warrants.","Post-close board elected: Matthew Foehr, Jennifer Cochran, Sarah Boyce, Sunil Patel, John Higgins, Carolyn Bertozzi, Joshua Tamaroff.","2022 Incentive Award Plan (14% of diluted shares) and ESPP (1.5% of diluted shares) approved, effective upon deal close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":358677,"accession_number":"0001104659-22-094427","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-08-25T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Avista Public Acquisition Corp. II appoints Charles Harwood to board and audit committee to regain Nasdaq compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Aug 22, 2022, company discussed Nasdaq Listing Rule 5605(c)(2) compliance after phase-in period.","Charles Harwood elected as director and appointed to Audit Committee on Aug 24, 2022.","Lâle White stepped down from Audit Committee; committee now has three independent members.","Harwood will receive a $10,000 fee upon completion of business combination.","Company states it is now in compliance with applicable Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377437,"accession_number":"0001104659-22-072746","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"APAC files OmniAb teach-in presentation with no new material facts beyond prior deal terms","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation attached as Exhibit 99.1 consists only of legal disclaimers and forward-looking statements.","No new transaction terms, financial projections, or material updates compared to March 23, 2022 definitive agreement.","Presentation used in connection with proposed business combination between APAC and OmniAb (Ligand subsidiary)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395827,"accession_number":"0001104659-22-037314","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-03-24T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Avista SPAC to combine with OmniAb (Ligand antibody business) at $850M pre-money value","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["OmniAb valued at $850M pre-money; earnout of up to 15M shares with $12.50/$15.00 VWAP targets.","Sponsor to purchase $15M in APAC common + warrants via Forward Purchase, backstop up to $100M for redemptions.","Transaction includes Distribution of OmniAb stock to Ligand shareholders immediately prior to Merger.","Post-closing APAC will redomicile to Delaware and list on Nasdaq under 'OABI' (warrants 'OABIW').","Conditions include HSR clearance, APAC shareholder approval, Nasdaq listing, and net tangible assets ≥$5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395826,"accession_number":"0001104659-22-037111","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"APAC to merge with Ligand's OmniAb antibody discovery business at $850M valuation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-money equity valuation of $850M; minimum $130M gross cash to combined company, up to $266M.","Avista commits up to $115M ($15M PIPE + $100M backstop); Ligand contributes $15M.","Ligand shareholders to own 75-84% of combined firm; APAC shareholders ~20%, Avista ~5%.","Transaction expected to close H2 2022; OmniAb to list on Nasdaq as 'OABI'.","Matt Foehr named CEO of OmniAb; Kurt Gustafson appointed CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395825,"accession_number":"0001104659-22-033379","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.03","9.01"],"status":"ready","headline":"Avista Public Acquisition Corp. II issues up to $750K promissory note to sponsor for working capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Unsecured note of up to $750,000 issued on March 14, 2022 to sponsor Avista Acquisition LP II.","Note bears no interest; repayable upon earlier of business combination or winding up of the SPAC.","Sponsor may convert all or part of note into warrants at $1.50 per warrant, identical to private placement warrants.","Proceeds used for working capital needs of the blank-check company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395824,"accession_number":"0001104659-22-008418","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K/A","filed_at":"2022-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avista Public Acquisition restates Aug 2021 balance sheet; reclassifies 23M shares to temporary equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restatement reclassifies all 23M Class A ordinary shares from permanent to temporary equity; no cash impact.","Material weakness in internal control over financial reporting identified; disclosure controls ineffective.","IPO raised $230M gross from 23M units at $10; private placement of 8.23M warrants added $12.35M.","Trust account holds $235.75M ($10.25 per share) as previously reported; no change from restatement.","Restatement corrects prior classification error; company concluded error would influence reasonable investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414671,"accession_number":"0001104659-21-145478","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Avista Public Acquisition Corp. II restates prior financials over share classification error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restating audited balance sheet as of Aug 12, 2021 and Q3 2021 financials due to classification error on redeemable Class A ordinary shares.","All Class A ordinary shares subject to possible redemption reclassified from permanent to temporary equity.","Material weakness identified in internal control over financial reporting; remediation plan to be filed in amended Q3 10-Q/A.","Restatement has no impact on cash position or trust account balance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432789,"accession_number":"0001104659-21-119820","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2021-09-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avista Public Acquisition Corp. II units separate into AHPA and AHPAW on Sept 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders of 23,000,000 units can elect to separately trade Class A ordinary shares (AHPA) and warrants (AHPAW) starting Sept 30, 2021.","Separated shares trade as AHPA, warrants as AHPAW; units continue as AHPAU on Nasdaq.","No fractional warrants will be issued; only whole warrants will trade upon separation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432788,"accession_number":"0001104659-21-107385","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2021-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avista Public Acquisition Corp. II closes $230M IPO plus $12.35M private placement; trust $235.75M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 23M units at $10 each, including full over-allotment; gross proceeds $230M.","Sponsor bought 8.233M private warrants at $1.50, raising $12.35M.","Net of deferred underwriting, $235.75M placed in trust — $10.25 per public share.","Balance sheet: $1.72M cash outside trust for working capital; equity $5.0M.","21.85M Class A shares subject to possible redemption at $224.0M temporary equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432787,"accession_number":"0001104659-21-104194","cik":1846253,"company_name":"OmniAb, Inc.","ticker":"OABI","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avista Public Acquisition Corp. II closes $230M IPO, $235.75M in trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 23M units at $10/unit, including full over-allotment of 3M units.","Gross proceeds $230M; private placement of 8.23M sponsor warrants grossed $12.35M.","Total $235.75M placed in trust account for future business combination.","Company targets healthcare industry for initial business combination.","Sponsor and officers entered into lock-up, registration, and other standard agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":375478975.0901961,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}